Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas
Neuro-Oncology · 01.02.2026 · 28 (2) · 485-494
DOI: 10.1093/neuonc/noaf246 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Neuro-Oncology, online erschienen am 16.10.2025. Verfasst von David Schiff und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuro-Oncology, University of Virginia School of Medicine, Charlottesville (D.S.). Hauptthemen laut MEDLINE: Glioma, Isocitrate Dehydrogenase, Brain Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Gateway for Cancer Research and Adult Brain Tumor Consortium, NCI NIH HHS, NIMHD NIH HHS.
Abstract (Originalsprache)
Background
Preclinical studies demonstrate activity of poly(adenosine 5’-diphosphate-ribose) polymerase (PARP) inhibitors in isocitrate dehydrogenase (IDH) mutant gliomas. We investigated safety, tolerability, pharmacokinetics, and efficacy of the PARP inhibitor pamiparib in conjunction with metronomic low-dose temozolomide in patients with recurrent IDH mutant (IDHmt) gliomas in a multicenter Phase I/II/window of opportunity study.
Methods
Patients received pamiparib in conjunction with daily temozolomide. Following Phase I determination of maximum tolerated dose (MTD), we enrolled 2 patient cohorts (Arm A, multiple prior chemotherapy regimens; Arm B, single prior regimen) in a 2-stage design. Exploratory cohorts examined grade 4 IDHmt patients and intratumoral pharmacokinetics of pamiparib. The primary endpoint was objective radiographic response (ORR) by RANO criteria.
Results
Sixty-six subjects were enrolled. We established pamiparib 60 mg twice daily with temozolomide 20 mg daily as the phase II dose. In non-enhancing and enhancing tumor, pamiparib exhibited an unbound tumor/plasma ratio of 0.92 and 0.98, respectively. 0/15 Arm A and 1/24 Arm B patients achieved a centrally confirmed partial response. Median progression-free survival for Arm A was 5.9 months (95% CI, 1.2-14.8 months), and for Arm B was 9.7 months (95% CI, 5.7-21.7 months). Grade 3+ anemia and neutropenia affected 24% and 33% of patients, respectively. Twenty-two of 66 patients (33.3%) discontinued study treatment for reasons other than tumor progression.
Conclusions
Pamiparib appeared to achieve sufficient pharmacologically active concentrations in both enhancing and non-enhancing tumors. While some patients achieved prolonged progression-free survival, combination with temozolomide did not produce a meaningful ORR in IDHmt recurrent gliomas. Cumulative hematologic toxicity was substantial and impacted long-term tolerability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neuro-Oncology, University of Virginia School of Medicine, Charlottesville (D.S.).
- Department of Neurosurgery, Johns Hopkins School of Medicine, Baltimore.
- Department of Oncology, Wayne State University, Detroit.
- Department of Radiological Sciences, David Geffen School of Medicine, UCLA, Los Angeles.
- Neuro-Oncology Center, Dana-Farber Cancer Institute, Boston.
- Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit.
ORCID-Profile: David Schiff, Benjamin M Ellingson, Tobias Walbert, Antonio Omuro, Ranjit S Bindra
Förderung
- Gateway for Cancer Research and Adult Brain Tumor Consortium
- NCI NIH HHS
- NIMHD NIH HHS
Zitieren
APA
Schiff, D., Ye, X., Li, J., Ellingson, B. M., Wen, P. Y., Walbert, T., Campian, J., Nabors, L. B., Ozer, B. H., Desai, A., Omuro, A., Desideri, S., Danda, N., Grossman, S., & Bindra, R. S. (2026). Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas. Neuro-Oncology, 28(2), 485-494. https://doi.org/10.1093/neuonc/noaf246
Vancouver
Schiff D, Ye X, Li J, Ellingson BM, Wen PY, Walbert T, et al. Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas. Neuro-Oncology. 2026;28(2):485-494. doi:10.1093/neuonc/noaf246
BibTeX
@article{Schiff2026,
author = {Schiff, David and Ye, Xiaobu and Li, Jing and Ellingson, Benjamin M and Wen, Patrick Y and Walbert, Tobias and Campian, Jian and Nabors, Louis B and Ozer, Byram H and Desai, Arati and Omuro, Antonio and Desideri, Serena and Danda, Neeraja and Grossman, Stuart and Bindra, Ranjit S},
title = {Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas},
journal = {Neuro-Oncology},
year = {2026},
volume = {28},
number = {2},
pages = {485--494},
doi = {10.1093/neuonc/noaf246}
}
EUVIMED